CTOs on the Move

InSightec

www.insightec.com

 
InSightec is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company`s non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.insightec.com
  • 801 Brickell Avenue Suite 1600
    Dallas, TX USA 33131
  • Phone: 786.534.3849

Executives

Name Title Contact Details

Funding

InSightec raised $22M on 01/07/2016
InSightec raised $150M on 12/14/2017

Similar Companies

Novartis

Novartis provides healthcare solutions that improve and extend people`s lives. We use science-based innovation to address some of society`s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our company is focused on industry-leading divisions with innovation power and global scale: pharmaceuticals, eye care and generic medicines Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 120,000 associates and its products are available in more than 180 countries around the world.

Canvas Health

Dedicated to bringing hope, healing and recovery to children, adolescents, adults and families struggling with mental health, chemical health and abuse.

Eko

Learn how Eko brings together stethoscopes, patient & provider software, and AI-powered analysis—elevating the way we detect and monitor cardiovascular disease.

LifeNet Health

LifeNet Health helps save lives, restore health, and give hope to thousands each year.

POZEN

POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.